Mark Auerbach - 23 Dec 2021 Form 3 Insider Report for PARDES BIOSCIENCES, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 23 Dec 2021
Net transaction value: $0
SEC form: 3
Accepted by SEC: 27 Dec 2021, 16:27:31 UTC
Next SEC filing: 10 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Lacy, attorney-in-fact

Key filing fact

Mark Auerbach filed Form 3 for PARDES BIOSCIENCES, INC. on 27 Dec 2021.

Key facts

This page summarizes Mark Auerbach's Form 3 filing for PARDES BIOSCIENCES, INC..
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 27 Dec 2021, 16:27.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PRDS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 70,390
Date: 23 Dec 2021
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

Exhibit 24 - Power of Attorney Effective immediately following the effective time of the merger pursuant to that certain Agreement and Plan of Merger dated as of June 29, 2021, as amended, by and among Pardes Biosciences Sub, Inc. (f/k/a Pardes Biosciences, Inc.), Issuer (f/k/a FS Development Corp. II), and certain other parties thereto, the reporting person became a director of the Issuer.